The multiple depletion curves method provides accurate estimates of intrinsic clearance (CLint), maximum velocity of the metabolic reaction (Vmax), and Michaelis constant (Km): Accuracy and robustness evaluated through experimental data and Monte Carlo simulations

Drug Metabolism and Disposition

Volumn 37, Issue 1, 2009, Pages 47-58

  Sjögren, Erik ^a   Lennernäs, Hans ^a   Andersson, Tommy B ^b   Gråsjö, Johan ^c   Bredberg, Ulf ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ANALYTIC METHOD; ARTICLE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME METABOLISM; ENZYME SUBSTRATE; MICHAELIS CONSTANT; MONTE CARLO METHOD; MULTIPLE DEPLETION CURVES METHOD; PRIORITY JOURNAL;

ENZYMES; HALF-LIFE; KINETICS; MONTE CARLO METHOD; PHARMACOKINETICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 58149465763     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.021477     Document Type: Article

References (28)

1. Audersson S, Hofmanu Y, Nordling A, Li XQ, Nivelius S, Audersson TB, Iugelmau-Sundberg M, and Johansson I (2005) Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime. Drug Metab Dispos 33:570-578.
2. Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Eugene D, Loeper J, Gauthier JC, Beaune P, Pompon D, et al. (1993) Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther 265:366-372.
3. Bousquet-Melou A, Laffout CM, Laroute V, and Toutain PL (2002) Modelling the loss of metabolic capacities of cultured hepatocytes: application to measurement of Michaelis-Menten kinetic parameters in in vitro systems. Xenobiotica 32:895-906.
4. Carlile DJ, Hakooz N, Bayliss MK, and Houston JB (1999) Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 47:625-635.
5. Clement B and Lopian K (2003) Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos 31:645-651.
6. Cummins CL, Jacobsen W, and Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045.
7. Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislén K, Fager G, and Gustafsson D (2003) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 31:294-305.
8. Fau D, Eugene D, Berson A, Letterou P, Fromenty B, Fisch C, and Pessayre D (1994) Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 269:954-962.
9. Houston JB and Carlile DJ (1997) Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29:891-922.
10. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharmacol Res 22:103-112.
11. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
12. Jones HM and Houston JB (2004) Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 32:973-982.
13. Jones HM, Nicholls G, and Houston JB (2005) Impact of end-product inhibition on the determination of in vitro metabolic clearance. Xenobiotica 35:439-454.
14. Kaphalia L, Kaphalia BS, Kumar S, Kanz MF, and Treinen-Moslen M (2006) Efficient high performance liquid chromatograph/ultraviolet method for determination of diclofenac and 4′-hydroxydiclofeuac in rat serum. J Chromatogr B Analyt Technol Bionied Life Sci 830:231-237.
15. Kerry NL, Somogyi AA, Mikus G, and Bochner F (1993) Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes. Biochem Pharmacol 45:833-839.
16. Kobayashi K, Urashima K, Shimada N, and Chiba K (2002). Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol 63:889-896.
17. Leibinger J and KapásM (1996) New and validated high-performance liquid chromatographic method for determination of hydroxyflutamide in human plasma. J Pharm Bionied Anal 14:1377-1381.
18. Ludden TM (1991) Nonlinear pharmacokinetics: clinical Implications. Clin Phamacokinet 20:429-446.
19. Masimirembwa CM, Bredberg U, and Andersson TB (2003) Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet 42:515-528.
20. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
21. Obach RS, Baxter JG, Listen TE, Silber BM, Jones BC, Maclntyre F, Ranee DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
22. Obach RS and Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated hiotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837.
23. Rane A, Wilkinson GR, and Shand DG (1977) Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 200:420-424.
24. Rodrigues AD (1997) Preclinical drug metabolism in the age of high-through put screening: an industrial perspective. Pharm Res 14:1504-1510.
25. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
26. Tang W, Stearns RA, Bandiera SM, Zhang Y, Raab C, Braun MP, Dean DC, Pang J, Leung KH, Doss GA, et al. (1999) Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab Dispos 27:365-372.
27. Tevell A, Lennernas H, Jönsson M, Norlin M, Leunemas B, Bondesson U, and Hedeland M (2006) Flutamide metabolism in four different species in vitro and identification of flutamide metabolites in human patient urine by high performance liquid chromatography/tandem mass spectrometry. Drug Metab Dispos 34:984-992.
28. Yu A and Haining RL (2001) Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 29:1514-1520.